Amidoimidazopyridazines as mknk-1 kinase inhibitors
US-2015376189-A1 · Dec 31, 2015 · US
US12497405B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12497405-B2 |
| Application number | US-202017783810-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2020 |
| Priority date | Dec 18, 2019 |
| Publication date | Dec 16, 2025 |
| Grant date | Dec 16, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising at least one Bicyclic Heterocycle Compound, and methods of using the Bicyclic Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
Opening claim text (preview).
What is claimed is: 1 . A compound of structural formula (I): or a pharmaceutically acceptable salt thereof, wherein: A is a bond or —O—; X is —N— or —C(R 2 )—; Y is —N— or —C(R 3 )—, such that only one of X and Y can be —N—; Z is —N— or —C(R 4 )—; R 1 is 5 to 7-membered monocyclic heterocycloalkyl or 9 or 10-membered bicyclic heterocycloalkyl, wherein said 5 to 7-membered monocyclic heterocycloalkyl group, and said 9 or 10-membered bicyclic heterocycloalkyl group can be optionally substituted with up to three R A groups, which can be the same or different, and wherein said 5 to 7-membered monocyclic heterocycloalkyl group, and said 9 or 10-membered bicyclic heterocycloalkyl group can optionally have a ring carbon atom functionalized as a carbonyl group; R 2 is selected from H, C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl), C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, —CN, —NH 2 , —C(O)O—(C 1 -C 6 alkyl), C 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalkyl, C 6 -C 10 aryl, 5 to 7-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl, wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 5 to 7-membered monocyclic heteroaryl group, and said 9 or 10-membered bicyclic heteroaryl group can be optionally substituted with up to three RB groups, which can be the same or different, or where R 2 and R 3 , together with atoms to which they are attached, are joined to form a 5-membered heteroaryl group; R 3 is selected from H, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, 5 to 7-membered monocyclic heteroaryl, —O—(5 to 7-membered monocyclic heteroaryl), C 3 -C 7 cycloalkyl, wherein said C 3 -C 7 cycloalkyl group, and any of said 5 to 7-membered monocyclic heteroaryl groups, can be optionally substituted with up to three RC groups, which can be the same or different; R 4 is selected from H, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, and C 3 -C 7 cycloalkyl; R 5 is selected from H, C 1 -C 6 alkyl, —OR 7 , —CN, —NH 2 , C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, —O—(C 1 -C 6 hydroxyalkyl), —(C 1 -C 6 alkylene)—NH—(C 1 -C 6 haloalkyl), —O—(C 1 -C 6 alkylene) m -(C 3 -C 7 cycloalkyl), —O—(C 1 -C 6 alkylene) m -(5 to 7-membered monocyclic heterocycloalkyl), and —(C 1 -C 6 alkylene) m -(5 to 7-membered monocyclic heterocycloalkyl), wherein said C 1 -C 6 alkyl group, said C 3 -C 7 cycloalkyl group, and said 5 to 7-membered monocyclic heterocycloalkyl group can each be optionally substituted with one or more substituents, each independently selected from —OH, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl, and wherein said C 1 -C 6 haloalkyl can be optionally substituted with one —NH 2 group; R 6 represents up to 3 phenyl ring substituents, which can be the same or different, and are each independently selected from C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —CN, —NO 2 , —OR 7 , and halo; each occurrence of R 7 is independently selected from H, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl; each occurrence of R A is independently selected from C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxyalkyl, 5 to 7-membered monocyclic heterocycloalkyl, —C(O)—(C 1 -C 6 alkyl), and halo, wherein said 5 to 7-membered monocyclic heterocycloalkyl group can be optionally substituted with up to 3 substituents, which can be the same or different, and are each independently selected from C 1 -C 6 alkyl, 5 to 7-membered monocyclic heterocycloalkyl, and halo; each occurrence of R B is independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, —O—(C 3 -C 7 cycloalkyl), —OR 7 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 alkylene) m -(5 to 7-membered monocyclic heterocycloalkyl), and —(C 1 -C 6 alkylene) m -(5 to 7-membered monocyclic heterocycloalkyl), and —NH 2 ; each occurrence of R C is independently selected from C 1 -C 6 alkyl, —OR 7 , C 1 -C 6 haloalkyl, and 5 to 7-membered monocyclic heterocycloalkyl; and each occurrence of m is independently 0 or 1. 2 . The compound of claim 1 , wherein —A—R 1 is: 3 . The compound of claim 1 , wherein X is N. 4 . The compound of claim 1 , wherein Y is N. 5 . The compound of claim 1 , wherein Z is N. 6 . The compound of claim 1 , wherein none of X, Y and Z is N. 7 . The compound of claim 1 , wherein R 2 is selected from H, —CN, cyclobutyl, pyrazolyl, pyridyl, trizolyl, oxazolyl, —CH 2 C(CH 3 ) 2 NH 2 , —CH 2 C(CH 3 ) 2 OH, —CH 2 CH(CH 3 ) OH, wherein said pyrazolyl group, said triazolyl group, said pyridyl group, and said cyclobutyl group can be optionally substituted with up to 2 groups, which are independently selected from —CHF 2 , —CF 3 , piperdinyl, —OCH 3 , —OH, and methyl. 8 . The compound of claim 1 , wherein Y is —C(R 3 )— and R 3 is selected from H, —O-pyrazolyl, oxazolyl, —CH 2 OH, —CH 2 C(CH 3 ) 2 OH, and —CH 2 CH(CH 3 )OH. 9 . The compound of claim 1 , wherein Z is —C(R 4 )— and R 4 is selected from H, —CH 2 OH, and cyclopropyl. 10 . The compound of claim 1 , wherein R 5 is selected from H, —OH, —OCH 3 , methyl, ethyl, and cyclopropyl. 11 . The compound of claim 1 , wherein X and Y are each —CH—. 12 . The compound of claim 1 , wherein R 6 is 4-Cl or 4-CN. 13 . The compound of claim 1 , wherein R 7 is H or methyl. 14 . A compound of the structure:
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Ortho-condensed systems · CPC title
containing three or more hetero rings · CPC title
for herpes viruses · CPC title
Oxygen atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.